[1]严 威,刘 宝.国家组织药品集中采购规则对药品中选价格的影响[J].卫生经济研究,2025,42(07):51-55,59.
　YAN Wei,LIU Bao.The Impact of National Centralized Volume-based Procurement Policies on Bid-Winning Drug Prices[J].Journal Press of Health Economics Research,2025,42(07):51-55,59.
点击复制

国家组织药品集中采购规则对药品中选价格的影响

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
42
期数:
2025年07期
页码:
51-55,59
栏目:
出版日期:
2025-07-01

文章信息/Info

Title:
The Impact of National Centralized Volume-based Procurement Policies on Bid-Winning Drug Prices
作者:
严 威1; 2; 刘 宝1; 2
1.复旦大学公共卫生学院，上海 200032
2.国家卫生健康委员会卫生技术评估重点实验室（复旦大学），上海 200032
Author(s):
YAN Wei;  LIU Bao
School of Public Health, Fudan University, Shanghai 200032, China
关键词:
药品; 国家组织药品集中采购; 价格; 约定采购量
Keywords:
drugs;  national centralized volume-based procurement of drugs;  price;  agreed procurement volume
分类号:
R95
文献标志码:
A
摘要:
目的：分析国家组织药品集中采购规则对药品中选价格的影响，为完善我国药品集中采购制度提供参考。方法：使用多元线性回归，分析国家集采规则和药品质量因素对药品中选价格的影响。结果：以“单位可比价≤同品种最低单位可比价1.8倍”规则中选的药品为基准，竞争性规则和“50%降幅”中选规则对药品价格降幅的影响较为显著，体现了国家集中采购以市场为主导的药品价格形成机制；企业在选择供应省份时，更倾向于选择约定采购量更大的省份。结论：当前我国药品集采规则对质量因素的考量不足，应科学设置集采报量和最高限价，建立综合评审体系，持续监测药品质量和供应情况。
Abstract:
Objective To analyze the impact of the national centralized volume-based procurement rules on the bid-winning drug prices, and to provide references for improving drug centralized volume-based procurement system and rules in China. Methods Multiple linear regression was used to analyze the impact of the national centralized volume-based procurement rules and the quality factors of drugs on the bid-winning drug prices. Results Taking the drugs selected based on the rule "unit comparable price≤1.8 times the lowest unit comparable price of the same variety" as the baseline, the price reduction of drugs selected under competitive rules and the rule "unit bid price reduction 50%" was more significant, which reflected the market-oriented drug price formation mechanism of national centralized volume-based purchasing. When selecting supply provinces, companies tended to prioritize provinces with larger procurement volumes. Conclusion The current centralized volume-based procurement rules in China lack sufficient consideration of quality factors of drugs. It is necessary to scientifically set agreed procurement volume and maximum bid price, establish a comprehensive evaluation system, and continuously monitor the quality and supply of drugs.

参考文献/References:

[1] 国家医疗保障局办公室.关于加强区域协同 做好2024年医药集中采购提质扩面的通知[EB/OL]. （2024-05-20）[2024-12-16].https://www.nhsa.gov.cn/art/2024/5/20/art_104_12745.html.
[2] 国务院办公厅.关于推动药品集中带量采购工作常态化制度化开展的意见[EB/OL] .（2021-01-28）[2024-12-16]. https://www.gov.cn/zhengce/content/2021-01/28/content_5583305.htm.
[3] Yuan J,Lu Z K,Xiong X,et al.Lowering drug prices and enhancing pharmaceutical affordability: an analysis of the national volume-based procurement(NVBP) effect in China [J].BMJ Glob Health, 2021,6(09):e005519.
[4] Zhu Z,Wang Q,Sun Q,et al.Improving access to medicines and beyond:the national volume-based procurement policy in China [J].BMJ Glob Health,2023,8(07):e011535.
[5] Yang Y,Chen L,Ke X,et al.The impacts of Chinese drug volume-based procurement policy on the use of policy-related antibiotic drugs in Shenzhen, 2018-2019:an interrupted time-series analysis[J].BMC Health Serv Res,2021,21(01):668.
[6] 国家组织药品联合采购办公室.全国药品集中采购文件（GY-YD2024-2）[EB/OL].（2024-11-12）[2024-12-16].https://www.smpaa.cn/gjsdcg/2024/11/22/15177.shtml.
[7] 甘李药业.全产品集采拟中标｜响应国家号召，以高品质胰岛素树立行业标杆[EB/OL].（2024-04-24）[2024-12-16].https://www.ganlee.com.cn/detail/1227.html.
[8] 国务院办公厅.关于印发国家组织药品集中采购和使用试点方案的通知[EB/OL].（2019-01-01）[2024-12-16].https://www.gov.cn/gongbao/content/2019/content_5361793.htm.
[9] 李毅仁，路云，常峰.基于企业报价博弈的药品带量采购规则研究[J].价格理论与实践，2020（01）：74-77，177.
[10] 李小瑜.我国药品集中带量采购价格机制研究[D].四川:四川大学，2022.
[11] 王彪，张天天，唐啸宇，等.我国集中带量采购中选药品价格差异及区域分布研究[J].中国卫生政策研究，2023，16（05）：29-33.
[12] 孙言，朱正，杨莉.国家组织药品集中带量采购价格降幅影响因素分析[J].中国卫生政策研究，2022，15（02）：54-59.
[13] 林丽敏，彭晓青，唐榕，等.国家药品集中采购政策对药品经济可及与医院用药结构的影响[J].中国药房，2023，34（24）：2968-2974.
[14] 郭丽，王健，王敬毅，等.药品集中采购政策对医院抗菌药物使用的影响研究[J].卫生经济研究，2022，39（06）：24-29.
[15] 何锐，葛靖，何梦娇，等.博弈论视角下药品带量采购降价的影响因素分析[J].中国药房，2020，31（09）：1025-1029.
[16] Dranitsaris G,Jacobs I,Kirchhoff C,et al.Drug tendering:drug supply and shortage implications for the uptake of biosimilars[J].Clinicoecon Outcomes Res,2017,9:573-584.
[17] Anto?觡anzas F,Juárez-castelló C,Rodríguez-ibeas R.Tenders for generics and biosimilars:a challenging purchasing policy[J].Eur J Health Econ,2023,24(04):485-487.
[18] Dylst P,Vulto A,Simoens S.Tendering for outpatient prescription pharmaceuticals: what can be learned from current practices in Europe?[J].Health Policy,2011,101(02):146-152.
[19] 罗巧，王之舟，刘文娜，等.格列美脲集采中选仿制药与原研药临床效果的真实世界研究[J].中国药业，2023，32（24）：50-54.
[20] 路云.基于价值医疗的地方药品集采质量水平综合评价体系研究[J].中国医疗保险，2023（12）：5-12.
[21] 徐源，金春林，宋捷，等.我国省级药品带量采购趋势研究[J]. 卫生经济研究，2024，41（05）：9-12.
[22] 国家组织药品集中采购和使用联合采购办公室.全国药品集中采购文件（GY-YD2019-2）[EB/OL].（2019-12-29）[2024-12-16].https://www.smpaa.cn/gjsdcg/2019/12/29/9205.shtml.

相似文献/References:

[1]陈新平.药品及耗材零差率改革对省级医院运行的影响与对策[J].卫生经济研究,2016,(05):42.
[2]姚奕婷,陈元栋,张远妮,等.广东省公立医院取消药品、医用耗材加成的效果研究[J].卫生经济研究,2020,(12):32.
　YAO YI-ting,CHEN Yuan-dong,ZHANG Yuan-ni,et al.Study on the Effect of Canceling the Addition of Drugs and Medical Consumables in Public Hospitals in Guangdong Province[J].Journal Press of Health Economics Research,2020,(07):32.
[3]李大双,颜建周,白铭钰,等.国家组织药品集中采购供应问题及对策研究[J].卫生经济研究,2022,39(6):12.
　LI Dashuang,YAN Jianzhou,BAI Mingyu,et al.Research on the Supply Problems and Countermeasures of National Centralized Drug Procurement[J].Journal Press of Health Economics Research,2022,39(07):12.
[4]欧阳明,李紫薇,高 明,等.深圳GPO模式及其对我国药品采购管理体制改革的启示[J].卫生经济研究,2022,39(9):53.
　OUYANG Ming,LI Ziwei,GAO Ming,et al.Drug Group Purchasing Organization (GPO) Model in Shenzhen and Its Enlightenment for the Reform of Drug Procurement Management System in China[J].Journal Press of Health Economics Research,2022,39(07):53.
[5]钱雨昕,王艳翚,姚峥嵘,等.政府在药品价格形成机制中的价值选择及路径优化研究[J].卫生经济研究,2023,40(11):30.
　QIAN Yuxin,WANG Yanhui,YAO Zhengrong,et al.Value Choice and Path Optimization of the Government in Drug Price Formation Mechanism[J].Journal Press of Health Economics Research,2023,40(07):30.
[6]王书平,孙 雯,吴 迪,等.紧密型县域医共体药物协同政策研究[J].卫生经济研究,2024,41(03):15.
　WANG Shuping,SUN Wen,WU Di,et al.Study on Drug Collaboration Policy of Compact County-level Medical Community[J].Journal Press of Health Economics Research,2024,41(07):15.

更新日期/Last Update: 2025-07-01